Pro 2013-023 (Jianfeng Group's 2012 Profit Distribution)
Release time:
2020-08-05
证券代码:600668证券简称:尖峰集团公告编号:临 2013-023
浙江尖峰集团股份有限公司 2012 年度利润分配实施公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
● 扣税前与扣税后每股现金红利
单位:元
每股现金红利(扣税前) 0.15
每股现金红利(扣税后) 0.1425
● 股权登记日
股权登记日 2013 年 7 月 19 日
● 除权(除息)日:2013 年 7 月 22 日
● 现金红利发放日
现金红利发放日 2013 年 7 月 26 日
浙江尖峰集团股份有限公司 2012 年度利润分配方案经 2013 年 5 月 31 日召开的公司
2012 年度股东大会审议通过。股东大会决议公告刊登于 2013 年 6 月 1 日的《中国证券报》、
《上海证券报》以及上海证券交易所网站(http://www.sse.com.cn)。
二、 分配方案
(一) 发放年度:2012 年度
(二) 发放范围:
截止 2013 年 7 月 19 日下午在上海证券交易所收市后,在中国证券登记结算有限责任公司 上海分公司登记在册的本公司全体股东。
(三)本次分配以 2012 年末股本 344,083,828 股为基数,向全体股东每 10 股派发现金红利
1.5 元(含税),扣税后每 10 股派发现金红利 1.425 元。共计派发股利 51612574.2 元。 (四) 扣税说明
1、对于个人股东(包括证券投资基金)的现金红利,根据《关于实施上市公司股息红 利差别化个人所得税政策有关问题的通知》(财税〔2012〕85 号)有关规定,公司暂按 5%的税率代扣个人所得税,扣税后实际每股派发现金红利 0.1425 元。如股东的持股期限
(持股期限是指个人从公开发行和转让市场取得上市公司股票之日至转让交割该股票之 日前一日的持有时间)在 1 个月以内(含 1 个月)的,其股息红利所得全额计入应纳税所
得额,实际税率 20%;持股期限在 1 个月以上至 1 年(含 1 年)的,实际税率 10%;持股 期限超过 1 年的,实际税率 5%。个人(包括证券投资基金)转让股票时,中登上海分公 司根据其持股期限计算实际应纳税额,超过已扣缴税款的部分,由证券公司等股份托管机 构从个人资金账户中扣收并划付中登上海分公司,中登上海分公司于次月 5 个工作日内划 付公司,公司在收到税款当月的法定申报期内向主管税务机关申报缴纳。
2、对于合格境外机构投资者(QFII)的现金红利,根据《关于中国居民企业向 QFII 支付股息、红利、利息代扣代缴企业所得税有关问题的通知》(国税函〔2009〕47 号)
(以下简称“《通知》”)相关规定,由公司按 10%的税率代扣代缴企业所得税,扣税后 实际每股派发现金红利 0.135 元。如相关股东认为其取得的股息收入需要享受任何税收协 定(安排)待遇的,股东可按照《通知》的规定在取得股息后自行向主管税务机关提出申 请。
3、对于机构投资者,其股息、红利所得税由其自行缴纳,实际每股派发税前现金红利
0.15 元。
三、 分配方案实施日期
(一) 股权登记日 2013 年 7 月 19 日
(二) 除权(除息)日:2013 年 7 月 22 日
(三) 现金红利发放日
现金红利发 2013 年 7 月 26 日
四、 分派对象
截止 2013 年 7 月 19 日(股权登记日)下午上海证券交易所收市后,在中国证券登记 结算有限责任公司上海分公司登记在册的本公司全体股东。
五、 分红、转增股本实施办法
(一)本公司股东金华市通济国有资产投资有限公司的现金红利由本公司直接发放。
(二)除金华市通济国有资产投资有限公司以外的本公司其他股东的现金红利,本公司委 托中国证券登记结算公司上海分公司通过其资金清算系统向股权登记日登记在册并在上 海证券交易所各会员办理了指定交易的股东派发。已办理全面指定交易的投资者可于红利
发放日在其指定的证券营业部领取现金红利,未办理指定交易的股东红利暂由中国证券登 记结算公司上海分公司保管,待办理指定交易后再进行派发。
六、 有关咨询办法
地址:浙江省金华市婺江东路 88 号尖峰大厦董事会办公室 电话:0579-82320582;传真:0579-82324666
七、 备查文件目录
本公司 2012 年度股东大会决议及公告。
浙江尖峰集团股份有限公司
董事会
2013 年 7 月 16 日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11